Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Abbott Laboratories

How Is Abbott Laboratories' Stock Performance Compared to Other Medical Devices Stocks?

Although Abbott Laboratories has underperformed its industry peers recently, analysts remain highly optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb or Sink?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Worried About a Stock Market Crash? These Dividend Stocks Can Help You Ride It Out

Discover four recession-resistant dividend stocks from stable sectors with decades of payout growth, low payout ratios, and strong analyst ratings.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Dividend Stocks With 100+ Years of History and Sky-High Growth

These three century-old companies boast strong buy ratings, 50%+ dividend growth, and rock-solid fundamentals—ideal picks for long-term income investors.

Barchart

Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield

Abbott Laboratories' dividend is safe, the pipeline is strong, and the outlook for growth is positive, making the July price dip a buying opportunity.

MarketBeat

Abbott Laboratories Sheds 8% On A Rare Guidance Miss

Abbott stock toppled Thursday after the health giant issued a light organic sales outlook for 2025, though it beat quarterly estimates.

Investors Business Daily

Forget Chasing Yields: These 3 Dividend Stocks Are Built to Last

Three top dividend growth stocks have strong fundamentals, analyst buy ratings, and decades of increases, found using Barchart’s free tool.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Abbott Laboratories Shows Improved Relative Price Performance; Still Shy Of Benchmark

Abbott Laboratories shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

3 Overlooked Dividend Aristocrats To Buy in 2025

These three dividend companies all share one common trait: strong earnings growth and rising cash flow.

Barchart

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

Barchart

What to Expect From Abbott Laboratories' Q2 2025 Earnings Report

Abbott is poised to release its second-quarter results next month, and analysts project a single-digit earnings growth.

Barchart

3 Under-The-Radar Dividend Aristocrats Set to Breakout in Q3

These three dividend companies all share one commonality: near-perfect buy ratings and breakout potential.

Barchart

3 Dirt-Cheap Dividend Aristocrats About to Explode Higher

These buy-rated Dividend Aristocrats are trading at rare discounts, offering strong yields, bullish ratings, and potential long-term upside.

Barchart

3 Dividend Growth Stocks To Buy and Hold Forever

These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Abbott Laboratories Stock Sees RS Rating Rise To 82

A Relative Strength Rating upgrade for Abbott Laboratories shows improving technical performance.

Barchart

3 Dividend Aristocrats With Explosive Earnings and Bulletproof Payouts

Discover 3 Dividend Aristocrats with high earnings growth, low payout ratios, and strong analyst ratings: perfect for long-term income investors.

Barchart

Abbott Laboratories Stock: Is ABT Outperforming the Health Care Sector?

Abbott Laboratories has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

The 3 Most Powerful Dividend Kings You’ve Probably Overlooked

These three Dividend Kings have strong cash flow and EPS growth, making a compelling case for long-term income investors.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 Dividend Aristocrats Quietly Dominating The Market in 2025

These three dividend stocks easily beat the S&P 500's return in 2025 while offering predictable earnings and dividend growth.

Barchart

3 Oversold Dividend Aristocrats Wall Street Says Are Ready to Rally

Markets rise on improving geopolitical sentiment, leaving some quality dividend stocks to remain oversold.

Barchart

Is Wall Street Bullish or Bearish on Abbott Laboratories Stock?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Wall Street’s Best-Kept Secret? These 3 Dividend Stocks Are Outperforming Big Tech

These three Dividend Kings are beating the market in 2025, offering strong yields, reliable growth, and solid analyst buy ratings.

MarketBeat

Tariff-Resistant Abbott Laboratories on Track for New Highs

Abbott Laboratories stock price is on track to hit a new high in 2025 and could do it before the end of the first half. Dividends and buybacks help.

Barchart

Stocks Extend Losses on Cautious Powell Remarks

The S&P 500 Index ($SPX ) (SPY ) today is down -2.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -3.29%. June E-mini S&P futures (ESM25 ) are down -2.16%, and June E-mini Nasdaq futures...

Investors Business Daily

Abbott Makes A Bullish Move, Shrugging Off Covid Test Malaise

Abbott stock jumped Wednesday despite a mixed first-quarter report thanks to light sales of its Covid tests.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.